

statsautoriseret revisionsfirma  
Stationspladsen 1 og 3  
3000 Helsingør  
CVR nr. 30 19 52 64

Tlf. 4921 8700  
Fax 4921 8750  
[www.kallermann.dk](http://www.kallermann.dk)

## **Tetrakit Technologies ApS**

Ole Maaløes Vej 3  
2200 København N

**CVR no. 42094943**

**Annual report 2022**

The annual report was presented and adopted at the annual general meeting of the Company on 9 June 2023

---

Andreas Tue Ingemann Jensen  
Chairman of the annual general meeting

## Contents

Management's Statement	3
Independent Auditors' Report	4
Company Information	6
Management's Review	7
Accounting Policies	8
Income Statement	10
Balance Sheet	11
Statement of changes in Equity	12
Notes	13

## Management's Statement

Today, Management has considered and adopted the Annual Report of Tetrakit Technologies ApS for the financial year 1 January 2022 - 31 December 2022.

The Annual Report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 31 December 2022 and of the results of the Company's operations for the financial year 1 January 2022 - 31 December 2022.

In our opinion, the Management's Review includes a true and fair account of the matters addressed in the review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Copenhagen, 15 May 2023

### Management

Andreas Tue Ingemann Jensen  
Managing director

Umberto Maria Battisti

Christian Bernard Matthijs Poulie

Matthias Manfred Herth

Vladimir Shalgunov

Cong Wang

### Board of Directors

Andreas Tue Ingemann Jensen

Umberto Maria Battisti

Christian Bernard Matthijs Poulie

Matthias Manfred Herth

Vladimir Shalgunov

## Independent Auditors' Report

### To the shareholders of Tetrakit Technologies ApS

#### Opinion

We have audited the financial statements of Tetrakit Technologies ApS for the financial year 1 January 2022 - 31 December 2022, which comprise an income statement, balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2022 and of the results of its operations for the financial year 1 January 2022 - 31 December 2022 in accordance with the Danish Financial Statements Act.

#### Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibility under those standards and requirements are further described in the "Auditors' responsibility for the Audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statement in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management considers necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern; disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting in preparing the financial statements unless Management either intends to either liquidate the Company or suspend operations, or has no realistic alternative but to do so.

#### The auditor's responsibility for the audit of the financial statements

Our responsibility is to obtain reasonable assurance as to whether the financial statements are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is no guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect material misstatements. Misstatements can arise from fraud or error and can be considered material if it would be reasonable to expect that these - either individually or collectively - could influence the economic decisions taken by the users of financial statements on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain an attitude of professional skepticism throughout the audit. We also:

- \* Identify and assess the risk of material misstatements in the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or override of internal control.

## Independent Auditors' Report

- \* Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- \* Evaluate whether the accounting policies used are appropriate and whether the accounting estimates and the related disclosures made by Management are reasonable.
- \* Conclude on whether Management's use of the going concern basis of accounting in preparing the financial statements is appropriate and, based on the audit evidence obtained, conclude on whether a material uncertainty exists relating to events or conditions, which could cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may imply that the Company can no longer remain a going concern.
- \* Evaluate the overall presentation, structure and contents of the financial statements, including note disclosures, and whether the financial statements reflect the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control which we identify during our audit.

### Statement on Management's Review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of opinion providing assurance regarding the Management's review.

Our responsibility in connection with our audit of the financial statements is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or with the knowledge we have gained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review meets the disclosure requirements in the Danish Financial Statements Act.

Based on our procedures, we are of the opinion that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements in the Danish Financial Statements Act. In our opinion, the Management's review is not materially misstated.

Elsinore, 15 May 2023

Kallermann Revision A/S - statsautoriseret revisionsfirma

CVR-no. 30195264

Rasmus Rolighed Asmussen

State Authorised Public Accountant

mne45874

## Company details

<b>Company</b>	Tetrakit Technologies ApS Ole Maaløes Vej 3 2200 København N CVR no. 42094943 Date of formation 2 February 2021 Registered office Copenhagen
<b>Management</b>	Andreas Tue Ingemann Jensen, Managing director Umberto Maria Battisti Christian Bernard Matthijs Poulie Matthias Manfred Herth Vladimir Shalgunov Cong Wang
<b>Board of Directors</b>	Andreas Tue Ingemann Jensen, Managing director Umberto Maria Battisti Christian Bernard Matthijs Poulie Matthias Manfred Herth Vladimir Shalgunov
<b>Auditors</b>	Kallermann Revision A/S - statsautoriseret revisionsfirma Stationspladsen 1 og 3 3000 Helsingør CVR no. 30195264

## Management's Review

### The Company's principal activities

The Company's principal activities consist in developing radiopharmaceuticals for the diagnosis and treatment of cancer.

### Development in activities and the financial situation

The Company's Income Statement of the financial year 1 January 2022 - 31 December 2022 shows a result of DKK -2.235.527 and the Balance Sheet at 31 December 2022 a total of DKK 4.118.927 and an equity of DKK -502.089.

The Company has lost its capital. The Management expects the capital to be reestablished by addition of new capital or by debt conversion.

In 2022, the Company secured its first two investments: one from the Bioinnovation Institute's Venture Lab program and another from angel investment. The research and development program commenced in March of that year and persisted until the end of it. The Company successfully produced and tested crucial diagnostic tools on animal models and intends to initiate preclinical therapeutic efficacy tests and first-in-human studies in 2023. Additionally, the Company strengthened its partnership with Copenhagen University Hospital (Rigshospitalet) as a provider of astatine-211. It is worth noting that the management team remained unchanged throughout the year.

In 2022, capital injections were received by the Company, primarily utilized to accelerate its research and development program. As anticipated, the Company did not generate any revenue during that year since its concentration was on R&D. The burn rate was kept low, while the work rate was elevated to accelerate our drug development progress.

The Company faces significant risks in the future, particularly the possible failure of specific radiopharmaceutical assets during preclinical and clinical testing. To address this risk, the Company is working to expand its pipeline and become a multi-asset company. This involves partnering with developers of complementary technologies, such as new targeting vectors.

The Company's strategy is centered on developing drugs utilizing the TetraKit platform and progressing critical therapeutic assets toward clinical trials.

### Post financial year events

After the end of the financial year, no events have occurred which may change the financial position of the entity substantially.

## Accounting Policies

### Reporting Class

The annual report has been presented in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, with the adoption of individual rules from class C.

The accounting policies applied remain unchanged from last year.

### Reporting currency

The annual report is presented in Danish kroner.

## Income statement

### Gross profit/loss

Gross profit is a combination of the items of revenue, other operating income, costs for raw materials and consumables and other external expenses.

### Revenue

Revenue is recognised in the income statement if the goods have been delivered and the risk has passed to the buyer before year-end and if the revenue can be reliably calculated and expected to be received. Revenue is recognised excluding VAT and all discounts granted are recognised in revenue.

Other operating income comprises items of a secondary nature to the activities of the enterprises.

### Other external expenses

Other external expenses include expenses for research and development, sales, advertising, administration, premises etc.

### Financial income and expenses

Financial income and expenses are recognised in the income statement based at the amounts that concern the financial year. Financial income and expenses include interest revenue and expenses, accounts payable and transactions in foreign currencies, and surcharges and allowances under the advance-payment of tax scheme.

### Tax on net profit for the year

Tax on net profit/loss for the year comprises current tax on expected taxable income of the year and the year's adjustment of deferred tax less the part of the tax of the year that relates to changes in equity. Current and deferred tax regarding changes in equity is recognised directly in equity.

The Company and the Danish associates are taxed jointly. The Danish income tax is distributed between profit- and loss-making Danish enterprises in relation to their taxable income (full distribution).

## Balance sheet

### Receivables

Receivables are measured at amortized cost which usually corresponds to the nominal value. The value is reduced by write-downs for expected bad debts.

### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand as well as short-term securities with a term of less than three months which can be converted directly into cash at bank and in hand and involve only an insignificant risk of value changes.

### Equity

Equity comprises the working capital and a number of equity items that may be statutory or stipulated in the articles of association.



## **Accounting Policies**

### **Deferred tax**

Deferred tax and the associated adjustments for the year are determined according to the liability method as the tax base of all temporary differences between carrying amounts and the tax bases of assets and liabilities.

Deferred tax assets, including the tax base of tax losses allowed for carryforward, are recognised at the value at which they are expected to be used, either by elimination in tax on future earnings or by set-off against deferred tax liabilities in enterprises within the same legal entity and jurisdiction.

Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation applicable at the balance sheet date when the deferred tax is expected to crystallize as current tax.

### **Current tax liabilities**

Current tax liabilities and current tax receivables are recognised in the balance sheet as estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

### **Other payables**

Other payables are measured at amortized cost, which usually corresponds to the nominal value.

**Income Statement**

	Note	2022 DKK	2021 DKK
<b>Gross profit</b>		<b>-987.987</b>	<b>0</b>
Staff costs	1	-1.470.073	0
<b>Profit from ordinary operating activities</b>		<b>-2.458.060</b>	<b>0</b>
Finance expenses		-122.251	-2.812
<b>Profit from ordinary activities before tax</b>		<b>-2.580.311</b>	<b>-2.812</b>
Tax expense	2	344.784	0
<b>Profit</b>		<b>-2.235.527</b>	<b>-2.812</b>
<b>Proposed distribution of results</b>			
Retained earnings		-2.235.527	-2.812
<b>Distribution of profit</b>		<b>-2.235.527</b>	<b>-2.812</b>

## Balance Sheet as of 31 December

	Note	2022 DKK	2021 DKK
<b>Assets</b>			
Other receivables		80.633	0
Short-term tax receivables		344.784	0
Contributed capital in arrears		6.595	0
<b>Receivables</b>		<b>432.012</b>	<b>0</b>
<b>Cash and cash equivalents</b>		<b>3.686.915</b>	<b>57.188</b>
<b>Current assets</b>		<b>4.118.927</b>	<b>57.188</b>
<b>Assets</b>		<b>4.118.927</b>	<b>57.188</b>
<b>Liabilities and equity</b>			
Contributed capital		62.826	60.000
Retained earnings		-564.915	-2.812
<b>Equity</b>		<b>-502.089</b>	<b>57.188</b>
Convertible debt instruments		4.095.014	0
<b>Long-term liabilities other than provisions</b>	3	<b>4.095.014</b>	<b>0</b>
Trade payables		345.639	0
Other payables		180.363	0
<b>Short-term liabilities other than provisions</b>		<b>526.002</b>	<b>0</b>
<b>Liabilities other than provisions within the business</b>		<b>4.621.016</b>	<b>0</b>
<b>Liabilities and equity</b>		<b>4.118.927</b>	<b>57.188</b>
Contingent liabilities	4		
Collaterals and assets pledged as security	5		

## Statement of changes in Equity

	<b>Contributed capital DKK</b>	<b>Share premium DKK</b>	<b>Retained earnings DKK</b>	<b>Total DKK</b>
Equity 1 January 2022	60.000	0	-2.812	57.188
Increase of capital	2.826	1.673.424	0	1.676.250
Profit (loss)	0	0	-2.235.527	-2.235.527
Transferred from share premium	0	-1.673.424	1.673.424	0
<b>Equity 31 December 2022</b>	<b>62.826</b>	<b>0</b>	<b>-564.915</b>	<b>-502.089</b>

## Notes

	<b>2022</b>	<b>2021</b>
	<b>DKK</b>	<b>DKK</b>
<b>1. Staff costs</b>		
Wages and salaries	1.466.539	0
Social security contributions	3.534	0
	<u><b>1.470.073</b></u>	<u><b>0</b></u>
Average number of employees	<u>3</u>	<u>0</u>
<b>2. Tax expense</b>		
Tax credit	-344.784	0
	<u><b>-344.784</b></u>	<u><b>0</b></u>
<b>3. Long-term liabilities</b>		
	<b>Due</b>	<b>Due</b>
	<b>after 1 year</b>	<b>within 1 year</b>
	<b>DKK</b>	<b>DKK</b>
	<b>after 5 years</b>	<b>DKK</b>
Convertible instruments	4.095.014	0
	<u><b>4.095.014</b></u>	<u><b>0</b></u>

**4. Contingent liabilities**

The Company is from 7 June 2022 jointly taxed with the other enterprises in the group and are jointly and severally liable for the taxes that concern the joint taxation.

The total amount appears from the annual report of Tetrakit Holdings ApS, CVR-no. 43 31 49 20 which is the administration company in the joint taxation.

**5. Collaterals and securities**

No securities or mortgages exist at the balance sheet date.